Tech Company Financing Transactions
FoRx Therapeutics Funding Round
On 12/18/2025, FoRx Therapeutics raised $50 million in Series A funding from EQT Life Sciences, M Ventures and Novartis Venture Fund.
Transaction Overview
Company Name
Announced On
12/18/2025
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG (poly (ADP-ribose) glycohydrolase) inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Lichtstrasse 35
Basel, 4056
Switzerland
Basel, 4056
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. FoRx scientists bring more than 20 years of experience in DNA replication stress and DNA Damage Response pathways.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tarig Bashir
Browse more venture capital transactions:
Prev: 12/18/2025: Endra AI venture capital transaction
Next: 12/18/2025: Imprint venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs